By Chris Barncard – University of Wisconsin News –
Parkinson’s patients are receiving a new investigational treatment after a successful study at the University of Wisconsin–Madison helped demonstrate the cell therapy’s safety in non-human primates and refine the method for its delivery. Now, the biotechnology company running the trial is reporting encouraging results.
Aspen Neuroscience recently announced they would enroll a third group of patients in their trial, called ASPIRO. The ASPIRO trial is referred to as Phase 1/2a, a stage designed to evaluate an investigational treatment’s safety and most effective dose in humans.
